Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8293709 | 0.91 | PTGS2 (0.46) | ABCB11PTGS2CYP1A2LMNATDP1 | |
| SCHEMBL6914541 | 0.90 | ABCB11 (0.57) | ABCB11PTGS2CYP1A2LMNATDP1 | |
| SCHEMBL8904523 | 0.90 | ABCB11 (0.45) | ABCB11PTGS2CYP1A2LMNATDP1 | |
| SCHEMBL8905945 | 0.89 | ABCB11 (0.44) | ABCB11PTGS2CYP1A2LMNATDP1 | |
| SCHEMBL8905879 | 0.89 | ABCB11 (0.44) | ABCB11PTGS2CYP1A2LMNATDP1 | |
| SCHEMBL8905668 | 0.89 | ABCB11 (0.46) | ABCB11PTGS2CYP1A2LMNATDP1 | |
| SCHEMBL8906143 | 0.88 | ABCB11 (0.43) | ABCB11PTGS2CYP1A2LMNATDP1 | |
| SCHEMBL27370570 | 0.88 | ABCB11 (0.57) | ABCB11PTGS2CYP1A2LMNATDP1 | |
| SCHEMBL8907153 | 0.87 | ABCB11 (0.42) | ABCB11PTGS2CYP1A2LMNATDP1 | |
| SCHEMBL9030442 | 0.87 | ABCB11 (0.42) | ABCB11PTGS2CYP1A2LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 308 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2796112-B2 | Degradable implantable medical devices | ELIXIR MEDICAL CORP (US) | 2023-08-09 | — | — | EP | claimed |
| EP-1509224-A1 | METHODS USING A COMBINATION OF A 3-HETEROARYL-2-INDOLINONE AND A CYCLOOXYGENASE-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2005-03-02 | — | — | EP | claimed |
| US-20040235925-A1 | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof | PHARMACIA CORPORATION | 2004-11-25 | — | — | US | claimed |
| US-20040204411-A1 | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof | PHARMACIA CORPORATION | 2004-10-14 | — | — | US | claimed |
| US-20040186154-A1 | Therapeutic combinations for cardiovascular and inflammatory indications | SEIBERT KAREN (US) | 2004-09-23 | — | — | US | claimed |
| EP-1435956-A2 | THERAPEUTIC COMBINATIONS FOR CARDIOVASCULAR AND INFLAMMATORY INDICATIONS | Pharmacia Corporation (US) | 2004-07-14 | — | — | EP | claimed |
| EP-1414526-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Pharmacia Corporation (US) | 2004-05-06 | — | — | EP | claimed |
| US-20040044028-A1 | Combinations of omega-3 fatty acids and cyclooxygenase-2 inhibitors for treatment or prevention of cardiovascular disease and treatment or prevention of cancer | PHARMACIA CORPORATION | 2004-03-04 | — | — | US | claimed |
| US-20030225054-A1 | Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-04 | — | — | US | claimed |
| WO-2003097044-A1 | METHODS USING A COMBINATION OF A 3-HETEROARYL-2-INDOLINONE AND A CYCLOOXYGENASE-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2003-11-27 | — | — | WO | claimed |
| US-20030199482-A1 | Therapeutic combinations for cardiovascular and inflammatory indications | PHARMACIA CORPORATION | 2003-10-23 | — | — | US | claimed |
| US-20030119895-A1 | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PHARMACIA CORPORATION | 2003-06-26 | — | — | US | claimed |
| US-20030114418-A1 | Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor | PHARMACIA CORPORATION | 2003-06-19 | — | — | US | claimed |
| US-20030114416-A1 | Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate | PHARMACIA CORPORATION | 2003-06-19 | — | — | US | claimed |
| US-20030087942-A1 | Method for the treatment and prevention of cachexia | WASHINGTON UNIVERSITY | 2003-05-08 | — | — | US | claimed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| WO-2002078625-A2 | THERAPEUTIC COMBINATIONS FOR CARDIOVASCULAR AND INFLAMMATORY INDICATIONS | PHARMACIA CORPORATION (US) | 2002-10-10 | — | — | WO | claimed |
| WO-2002078626-A2 | THERAPEUTIC COMBINATIONS FOR CARDIOVASCULAR AND INFLAMMATORY INDICATIONS | PHARMACIA CORPORATION (US) | 2002-10-10 | — | — | WO | claimed |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2002-08-01 | — | — | US | claimed |
| JP-8208639-A | — | — | None | — | — | JP | disclosed |
| CN-122076675-A | Systems and methods for delivering therapeutic agents | — | 2026-05-26 | — | — | CN | disclosed |
| EP-3411159-B1 | SYSTEMS AND METHODS FOR DELIVERING THERAPEUTIC AGENTS | THERADEP TECH INC (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-3509604-B1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TUFTS COLLEGE (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260027079-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | EPM IP INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-20260007660-A1 | TREATMENT AND PREVENTION OF SLEEP DISORDERS | PURDUE PHARMA L.P. (US) | 2026-01-08 | — | — | US | disclosed |
| US-12478609-B2 | Combination therapies using immuno-DASH inhibitors and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2025-11-25 | — | — | US | disclosed |
| US-12384786-B2 | Cyclic molecules as Bruton's tyrosine kinase inhibitor | MINGHUI PHARMACEUTICAL SHANGHAI LTD (CN) | 2025-08-12 | — | — | US | disclosed |
| US-12370191-B2 | Treatment and prevention of sleep disorders | PURDUE PHARMA L.P. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250223554-A1 | METHODS AND COMPOSITIONS USING RECOMBINANT DENDRITIC CELLS FOR CANCER THERAPY | RENOVARO BIOPHARMA INC. | 2025-07-10 | — | — | US | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250145587-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2025-05-08 | — | — | US | disclosed |
| US-20250134886-A1 | SLEEP DISORDER TREATMENT AND PREVENTION | PURDUE PHARMA L.P. (US) | 2025-05-01 | — | — | US | disclosed |
| CN-114634575-B | Development and application of complement inhibitor | 康诺亚生物医药科技（成都）有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-112703004-B | Methods and compositions for cancer treatment using recombinant dendritic cells | 雷诺瓦罗生物制药公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| US-12171762-B2 | Sleep disorder treatment and prevention | PURDUE PHARMA L.P. (US) | 2024-12-24 | — | — | US | disclosed |
| EP-4474383-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2024-12-11 | — | — | EP | disclosed |
| US-20240360124-A1 | Bromodomain Inhibitors | ABBVIE INC. (US) | 2024-10-31 | — | — | US | disclosed |
| CN-118831076-A | Cannabinoid acid ester compositions and uses thereof | EPM (IP)公司 | 2024-10-25 | — | — | CN | disclosed |
| US-20240318174-A1 | Multi-Valent Oligonucleotide Agent and Methods of Use Thereof | RACTIGEN THERAPEUTICS (CN) | 2024-09-26 | — | — | US | disclosed |
| US-20240285611-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240277659-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2024-08-22 | — | — | US | disclosed |
| EP-3978191-B1 | ABRASIVE BLAST MODIFICATION OF SURFACES | ENBIO LTD (IE) | 2024-08-07 | — | — | EP | disclosed |
| US-20240228665-A1 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | OMEROS CORPORATION | 2024-07-11 | — | — | US | disclosed |
| CN-114246953-B | Anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-114177308-B | Anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-113840598-B | Cannabinoid acid ester compositions and uses thereof | EPM (IP)公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20240197757-A1 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL 2 FAMILY INHIBITOR | ABBVIE DEUTSCHLAND (DE) | 2024-06-20 | — | — | US | disclosed |
| US-11964943-B2 | 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of Stat3 pathway activity and uses thereof | KIAKOS KONSTANTINOS (AT) | 2024-04-23 | — | — | US | disclosed |
| US-11957657-B2 | Combination therapies using immuno-dash inhibitors and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2024-04-16 | — | — | US | disclosed |
| US-20240076408-A1 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | OMEROS CORPORATION | 2024-03-07 | — | — | US | disclosed |
| US-20240074882-A1 | BIODEGRADABLE ENDOPROSTHESES AND METHODS FOR THEIR FABRICATION | ELIXIR MEDICAL CORPORATION (US) | 2024-03-07 | — | — | US | disclosed |
| US-20240067751-A1 | DEVELOPMENT AND APPLICATION OF COMPLEMENT INHIBITOR | KEYMED BIOSCIENCES CO.,LTD (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240058333-A1 | TREATMENT AND PREVENTION OF SLEEP DISORDERS | PURDUE PHARMA L.P. (US) | 2024-02-22 | — | — | US | disclosed |
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20240043404-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-11884742-B2 | Methods for treating conditions associated with MASP-2 dependent complement activation | OMEROS CORPORATION (US) | 2024-01-30 | — | — | US | disclosed |
| CN-117377764-A | Multivalent oligonucleotide reagents and methods of use thereof | 中美瑞康核酸技术(南通)研究院有限公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-4288542-A1 | MULTI-VALENT OLIGONUCLEOTIDE AGENT AND METHODS OF USE THEREOF | Ractigen Therapeutics (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-20230391889-A1 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | OMEROS CORPORATION | 2023-12-07 | — | — | US | disclosed |
| US-20230390241-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-12-07 | — | — | US | disclosed |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| EP-2435432-B3 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE IRELAND UNLIMITED CO (BM) | 2023-10-25 | — | — | EP | disclosed |
| EP-4265641-A1 | DEVELOPMENT AND APPLICATION OF COMPLEMENT INHIBITOR | Keymed Biosciences Co.,Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| US-11786519-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230321271-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE BIOTHERAPEUTICS INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11772126-B2 | Systems and methods for delivering therapeutic agents | THERADEP TECHNOLOGIES INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230293516-A1 | SLEEP DISORDER TREATMENT AND PREVENTION | PURDUE PHARMA L.P. (US) | 2023-09-21 | — | — | US | disclosed |
| CN-111454268-B | Cyclic molecules as inhibitors of bruton's tyrosine kinase | 明慧医药（上海）有限公司 | 2023-09-08 | — | — | CN | disclosed |
| EP-4233909-A2 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Biotherapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11738023-B2 | Treatment and prevention of sleep disorders | PURDUE PHARMA L.P. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230263772-A1 | COMPOSITIONS AND METHODS FOR TREATING PAIN AND/OR INFLAMMATION | NEUMENTUM INC (US) | 2023-08-24 | — | — | US | disclosed |
| CN-116589465-A | Cyclic molecules as inhibitors of bruton's tyrosine kinase | 明慧医药（上海）有限公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-2796112-B2 | Degradable implantable medical devices | ELIXIR MEDICAL CORP (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-4218731-A2 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | AbbVie Ireland Unlimited Company (IE) | 2023-08-02 | — | — | EP | disclosed |
| EP-3322482-B1 | TOPICAL CIPROFLOXACIN COMPOSITIONS | TAP PHARMACEUTICALS AG (CH) | 2023-07-26 | — | — | EP | disclosed |
| US-20230202964-A1 | CANNABIGEROLIC ACID (CDGA) DERIVATIVES AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-06-29 | — | — | US | disclosed |
| US-20230192588-A1 | CANNABIDIOLIC ACID (CBDA) DERIVATIVES AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-06-22 | — | — | US | disclosed |
| US-20230165839-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| CN-114853753-B | Pyrido [1,2-a ] pyrimidinone analogs and their use in preparing FGFR inhibitors | 四川大学 | 2023-05-09 | — | — | CN | disclosed |
| CN-113710671-B | Cyclic molecules as inhibitors of bruton's tyrosine kinase | 明慧医药（上海）有限公司 | 2023-04-28 | — | — | CN | disclosed |
| EP-3370775-B1 | COMBINATION OF BCL-2 INHIBITOR AND MEK INHIBITOR FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2023-04-19 | — | — | EP | disclosed |
| EP-4161900-A1 | CANNABIDIOLIC ACID (CBDA) DERIVATIVES AND USES THEREOF | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2023-04-12 | — | — | EP | disclosed |
| US-20230101559-A1 | Bromodomain Inhibitors | ABBVIE INC (US) | 2023-03-30 | — | — | US | disclosed |
| EP-4137160-A1 | ANTIBODY DRUG CONJUGATE (ADC) PURIFICATION | AbbVie Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-02-21 | — | — | US | disclosed |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-02-21 | — | — | US | disclosed |
| US-11576913-B2 | Sleep disorder treatment and prevention | PURDUE PHARMA L.P. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20230039309-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-02-09 | — | — | US | disclosed |
| CN-109422749-B | Pyrimidinedione derivative for inhibiting monocarboxylic acid transporter | 重庆医药工业研究院有限责任公司 | 2023-01-24 | — | — | CN | disclosed |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2023-01-24 | — | — | US | disclosed |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2023-01-24 | — | — | US | disclosed |
| CN-109789205-B | anti-PD-1 (CD 279) antibodies | 艾伯维生物制药股份有限公司 | 2022-12-13 | — | — | CN | disclosed |
| US-20220315555-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2022-10-06 | — | — | US | disclosed |
| US-20220265667-A1 | ETIFOXINE FOR USE IN THE TREATMENT OF DISEASES RELATED TO ACTIVATED MAST CELLS | MC SCIENCES UG (DE) | 2022-08-25 | — | — | US | disclosed |
| US-11413338-B2 | Methods and compositions using recombinant dendritic cells for cancer therapy | Enochian BioPharma, Inc. (US) | 2022-08-16 | — | — | US | disclosed |
| WO-2022166849-A1 | MULTI-VALENT OLIGONUCLEOTIDE AGENT AND METHODS OF USE THEREOF | RACTIGEN THERAPEUTICS (CN) | 2022-08-11 | — | — | WO | disclosed |
| CN-114853753-A | Pyrido [1,2-a ] pyrimidone analogs and application thereof in preparation of FGFR inhibitor | 四川大学 | 2022-08-05 | — | — | CN | disclosed |
| EP-3288931-B2 | CERTAIN PROTEIN KINASE INHIBITOR | CHONGQING FOCHON PHARMACEUTICAL CO LTD (CN) | 2022-07-20 | — | — | EP | disclosed |
| CN-109535155-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维公司 | 2022-07-12 | — | — | CN | disclosed |
| US-11369599-B2 | Melt-extruded solid dispersions containing an apoptosis-inducing agent | ABBVIE INC. (US) | 2022-06-28 | — | — | US | disclosed |
| WO-2022127834-A1 | DEVELOPMENT AND APPLICATION OF COMPLEMENT INHIBITOR | 康诺亚生物医药科技（成都）有限公司 | 2022-06-23 | — | — | WO | disclosed |
| CN-114634575-A | Development and application of complement inhibitor | 康诺亚生物医药科技（成都）有限公司 | 2022-06-17 | — | — | CN | disclosed |
| US-20220175797-A1 | OPHTHALMOLOGIC IRRIGATION SOLUTIONS AND METHOD | OMEROS CORP (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220170163-A1 | ABRASIVE BLAST MODIFICATION OF SURFACES | ENBIO LIMITED (IE) | 2022-06-02 | — | — | US | disclosed |
| US-20220151972-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | EPM (IP), INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220125796-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-20220110951-A1 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL 2 FAMILY INHIBITOR | ABBVIE DEUTSCHLAND (DE) | 2022-04-14 | — | — | US | disclosed |
| EP-3978191-A1 | ABRASIVE BLAST MODIFICATION OF SURFACES | Enbio Limited (IE) | 2022-04-06 | — | — | EP | disclosed |
| CN-114246953-A | anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-109689058-B | Treatment and prevention of sleep disorders | 普渡制药公司 | 2022-03-22 | — | — | CN | disclosed |
| US-20220081445-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | MINGHUI PHARMACEUTICAL SHANGHAI LTD (CN) | 2022-03-17 | — | — | US | disclosed |
| CN-114177308-A | anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-20220040149-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2022-02-10 | — | — | US | disclosed |
| CN-113993846-A | Compositions and methods for treating pain and/or inflammation | 诺门图姆股份有限公司 | 2022-01-28 | — | — | CN | disclosed |
| EP-3937925-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | EPM (IP), Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| CN-113840598-A | Cannabinoid acid ester compositions and uses thereof | EPM (IP)公司 | 2021-12-24 | — | — | CN | disclosed |
| US-20210353652-A1 | TUMOR MICROENVIRONMENT-ACTIVATED DRUG-BINDER CONJUGATES, AND USES RELATED THERETO | AVACTA LIFE SCIENCES, LIMITED (GB) | 2021-11-18 | — | — | US | disclosed |
| WO-2020186010-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | EPM GROUP, INC. (US) | 2020-09-17 | — | — | WO | disclosed |
| US-20200054655-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2020-02-20 | — | — | US | disclosed |
| US-20190209525-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2019-07-11 | — | — | US | disclosed |
| US-9724362-B2 | Pharmaceutical compositions comprising nanoparticles and a resuspending material | BEND RESEARCH, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9545384-B2 | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate | BEND RESEARCH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| WO-2016177776-A1 | BIOMARKERS FOR THE DETECTION OF ASPIRIN INSENSITIVITY | ACADEMISCH MEDISCH CENTRUM (NL) | 2016-11-10 | — | — | WO | disclosed |
| EP-2231169-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES AND A RESUSPENDING MATERIAL | BEND RES INC (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-2162120-B1 | NANOPARTICLES COMPRISING A NON-IONIZABLE CELLULOSIC POLYMER AND AN AMPHIPHILIC NON-IONIZABLE BLOCK COPOLYMER | BEND RES INC (US) | 2016-05-04 | — | — | EP | disclosed |
| US-8974827-B2 | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer | BEND RESEARCH, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8309129-B2 | Nanoparticles comprising a drug, ethylcellulose, and a bile salt | BEND RESEARCH, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2178519-B1 | Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer | BEND RES INC (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20110130390-A1 | Use of COX-2 Inhibitors for the Treatment of Schizophrenia, Delusional Disorders, Affective Disorders, Autism or Tic Disorders | MUELLER NORBERT | 2011-06-02 | — | — | US | disclosed |
| US-20100323014-A1 | NANOPARTICLES COMPRISING A NON-IONIZABLE CELLULOSIC POLYMER AND AN AMPHIPHILIC NON-IONIZABLE BLOCK COPOLYMER | PFIZER INC. | 2010-12-23 | — | — | US | disclosed |
| US-20100310663-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES AND A RESUSPENDING MATERIAL | LONZA BEND INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100266692-A1 | NANOPARTICLES COMPRISING A NON-IONIZABLE POLYMER AND AN ANIONIC CELLULOSIC POLYMER | BEND RESEARCH, INC. | 2010-10-21 | — | — | US | disclosed |
| EP-2231169-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES AND A RESUSPENDING MATERIAL | BEND RESEARCH, INC. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20100215747-A1 | NANOPARTICLES COMPRISING IONIZABLE, POORLY WATER SOLUBLE CELLULOSIC POLYMERS | BEND RESEARCH, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100183731-A1 | NANOPARTICLES COMPRISING DRUG, A NON-IONIZABLE CELLULOSIC POLYMER AND TOCOPHERYL POLYETHYLENE GLOCOL SUCCINATE | LONZA BEND INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100119603-A1 | NANOPARTICLES COMPRISING A DRUG,ETHYCELLULOSE,AND A BILE SALT | PFIZER INC. | 2010-05-13 | — | — | US | disclosed |
| EP-2178519-A2 | NANOPARTICLES COMPRISING A NON-IONIZABLE POLYMER AND AN ANIONIC CELLULOSIC POLYMER | Bend Research, Inc (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-2178518-A2 | NANOPARTICLES COMPRISING IONIZABLE, POORLY WATER SOLUBLE CELLULOSIC POLYMERS | Bend Research, Inc (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20100080852-A1 | PHAMACEUTICAL COMPOSITION COMPRISING NANOPARTICLES AND CASEIN | BEND RESEARCH, INC. | 2010-04-01 | — | — | US | disclosed |
| EP-2162120-A2 | NANOPARTICLES COMPRISING A NON-IONIZABLE CELLULOSIC POLYMER AND AN AMPHIPHILIC NON-IONIZABLE BLOCK COPOLYMER | Bend Research, Inc (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20100062073-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES COMPRISING ENTERIC POLYMERS CASEIN | BEND RESEARCH, INC. | 2010-03-11 | — | — | US | disclosed |
| US-20090291883-A1 | COMBINATION OF AN IMMUNOSUPPRESSIVE AGENT AND NONSTEROIDAL ANTI -INFLAMMATORY DRUGS TO TREAT DISEASE | BOSTON MEDICAL CENTER CORPORATION (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090197833-A1 | Silicon Containing Compounds Having Selective Cox-2 Inhibitory Activity and Methods of Making and Using the Same | ENGLEBIENNE & ASSOCIATES (BE) | 2009-08-06 | — | — | US | disclosed |
| US-20090197833-A1 | Silicon Containing Compounds Having Selective Cox-2 Inhibitory Activity and Methods of Making and Using the Same | ENGLEBIENNE & ASSOCIATES (BE) | 2009-08-06 | — | — | US | disclosed |
| WO-2009073215-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES AND A RESUSPENDING MATERIAL | BEND RESEARCH, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| US-7521435-B2 | Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same | PHARMA DIAGNOSTICS, N.V. (BE) | 2009-04-21 | — | — | US | disclosed |
| US-7521435-B2 | Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same | PHARMA DIAGNOSTICS, N.V. (BE) | 2009-04-21 | — | — | US | disclosed |
| WO-2009010842-A2 | NANOPARTICLES COMPRISING IONIZABLE, POORLY WATER SOLUBLE CELLULOSIC POLYMERS | PFIZER PRODUCTS INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009010837-A2 | NANOPARTICLES COMPRISING A NON-IONIZABLE POLYMER AND AN ANIONIC CELLULOSIC POLYMER | PFIZER PRODUCTS INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2008149192-A2 | NANOPARTICLES COMPRISING A NON-IONIZABLE CELLULOSIC POLYMER AND AN AMPHIPHILIC NON-IONIZABLE BLOCK COPOLYMER | PFIZER PRODUCTS INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008149230-A2 | NANOPARTICLES COMPRISING DRUG, A NON-IONIZABLE CELLULOSIC POLYMER AND TOCOPHERYL POLYETHYLENE GLYCOL SUCCINATE | PFIZER PRODUCTS INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080293679-A1 | Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of COX inhibitors | CARDAX PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293679-A1 | Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of COX inhibitors | CARDAX PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| WO-2008135828-A2 | NANOPARTICLES COMPRISING A DRUG, ETHYLCELLULOSE, AND A BILE SALT | PFIZER PRODUCTS INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008135829-A2 | NANOPARTICLES COMPRISING COX-2 INHIBITORS AND A NON-IONIZABLE POLYMER | PFIZER PRODUCTS INC. (GB) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008135852-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES AND CASEIN | PFIZER PRODUCTS INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20080227845-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | CHEN YING-NAN PAN | 2008-09-18 | — | — | US | disclosed |
| US-20080227845-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | CHEN YING-NAN PAN | 2008-09-18 | — | — | US | disclosed |
| US-7402603-B2 | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination | NOVARTIS AG (CH) | 2008-07-22 | — | — | US | disclosed |
| US-7402603-B2 | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination | NOVARTIS AG (CH) | 2008-07-22 | — | — | US | disclosed |
| WO-2008065502-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON A) NANOPARTICLES COMPRISING ENTERIC POLYMERS AND B) CASEIN | PFIZER PRODUCTS INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| EP-1915992-A1 | USE OF CYCLOOXYGENASE INHIBITORS AND ANTIMUSCARINIC AGENTS FOR THE TREATMENT OF INCONTINENCE | Pharmacia Corporation (US) | 2008-04-30 | — | — | EP | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070149591-A1 | Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury | STEPHENSON DIANE T | 2007-06-28 | — | — | US | disclosed |
| US-20070149591-A1 | Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury | STEPHENSON DIANE T | 2007-06-28 | — | — | US | disclosed |
| US-20070149591-A1 | Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury | STEPHENSON DIANE T | 2007-06-28 | — | — | US | disclosed |
| EP-1608361-A4 | COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND 5-HT1B/1D AGONISTS FOR THE TREATMENT AND PREVENTION OF MIGRAINE | PHARMACIA CORP (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2006-07-20 | — | — | US | disclosed |
| US-20060135506-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders | PHARMACIA CORPORATION | 2006-06-22 | — | — | US | disclosed |
| EP-1660079-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20060105961-A1 | Method of using a cox-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia | PHARMACIA CORPORATION (US) | 2006-05-18 | — | — | US | disclosed |
| EP-1643995-A1 | TREATMENT OF MIGRAINE ACCOMPANIED BY NAUSEA | Pharmacia Corporation (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1140192-B1 | USE OF THE CYCLOOXYGENASE-2 INHIBITOR CELECOXIB AND CAPECITABINE FOR COMBINATION THERAPY IN NEOPLASIA | SEARLE LLC (US) | 2006-04-05 | — | — | EP | disclosed |
| EP-1608361-A2 | COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND 5-HT1B/1D AGONISTS FOR THE TREATMENT AND PREVENTION OF MIGRAINE | Pharmacia Corporation (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2005105099-A1 | MONOTHERAPY FOR THE TREATMENT OF PSORIASIS WITH CYCLOOXYGENASE-2 SELECTIVE INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005099691-A1 | COMPOSITION FOR TREATING ELEVATED INTRAOCULAR PRESSURE | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005097110-A1 | MONOTHERAPY FOR THE MODULATION OF INTRAOCULAR PRESSURE WITH CYCLOOXYGENASE-2 SELECTIVE INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050227929-A1 | Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent | PHARMACIA & UPJOHN, LLC | 2005-10-13 | — | — | US | disclosed |
| EP-1575594-A2 | COMBINATION OF REBOXETINE AND A CYCLOOXYGENASE-2 INHIBITOR | Pharmacia Corporation (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1572186-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HERPES VIRUS INFECTIONS USING CYCLOOXYGENASE-2 SELECTIVE INHIBITORS OR CYCLOOXYGENASE-2 INHIBITORS IN COMBINATION WITH ANTIVIRAL AGENTS | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050187172-A1 | Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia | PFIZER INC. | 2005-08-25 | — | — | US | disclosed |
| US-20050159419-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage | PHARMACIA CORPORATION (US) | 2005-07-21 | — | — | US | disclosed |
| US-20050159403-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-07-21 | — | — | US | disclosed |
| US-20050148589-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a neurotrophic factor-modulating agent for the treatment of central nervous system mediated disorders | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050143360-A1 | Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea | PHARMACIA CORPORATION | 2005-06-30 | — | — | US | disclosed |
| US-20050130971-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury | PHARMACIA CORPORATION | 2005-06-16 | — | — | US | disclosed |
| EP-1539142-A2 | USE OF AN AMYLOID BETA VACCINATION IN COMBINATION WITH A SELECTIVE COX-2 INHIBITOR FOR THE TREATMENT OF ALZHEIMER S DISEASE | Pharmacia Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1539169-A2 | AMYOTROPHIC LATERAL SCLEROSIS TREATMENT WITH CYCLOOXYGENASE-2 INHIBITORS | Pharmacia Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1536863-A1 | USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THROMBOLYTIC AGENTS FOR THE TREATMENT OR PREVENTION OF A VASO-OCCLUSIVE EVENT | Pharmacia Corporation (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20050113376-A1 | Compositions of a cyclooxygenase-2 selective inhibitor, a xanthine compound and an alcohol for the treatment of ischemic mediated central nervous system disorders or injury | PHARMACIA CORPORATION | 2005-05-26 | — | — | US | disclosed |
| US-20050113434-A1 | Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury | PHARMACIA CORPORATION | 2005-05-26 | — | — | US | disclosed |
| WO-2005046615-A2 | COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM MEDIATED DISORDERS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005044194-A2 | TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | WO | disclosed |
| US-20050107387-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | US | disclosed |
| US-20050101597-A1 | Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-05-12 | — | — | US | disclosed |
| WO-2005039565-A1 | COMBINATIONS OF COX AND VASOPRESSIN INHIBITORS FOR THE TREATMENT OF DISMENORRHEA | PFIZER LIMITED (GB) | 2005-05-06 | — | — | WO | disclosed |
| EP-1526869-A1 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CARBONIC ANHYDRASE INHIBITOR FOR THE TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2005-05-04 | — | — | EP | disclosed |
| WO-2005037193-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR ADMINISTERED UNDER HYPOTHERMIC CONDITIONS FOR THE TREATMENT OF ISCHEMIC MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20050085478-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-21 | — | — | US | disclosed |
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | PHARMACIA CORPORATION | 2005-04-21 | — | — | US | disclosed |
| US-20050085479-A1 | Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury | PHARMACIA CORPORATION | 2005-04-21 | — | — | US | disclosed |
| US-20050080083-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin II receptor antagonist for the treatment of central nervous system damage | PHARMACIA CORPORATION (US) | 2005-04-14 | — | — | US | disclosed |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-14 | — | — | US | disclosed |
| US-20050075341-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury | PHARMACIA CORPORATION (US) | 2005-04-07 | — | — | US | disclosed |
| US-20050070524-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders | PHARMACIA CORPORATION | 2005-03-31 | — | — | US | disclosed |
| US-20050065154-A1 | Treatment of migraine accompanied by nausea with a combination of cyclooxygenase-2 selective inhibitors and anti-nausea agents | PHARMACIA CORPORATION | 2005-03-24 | — | — | US | disclosed |
| US-20050054646-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders | PHARMACIA CORPORATION | 2005-03-10 | — | — | US | disclosed |
| WO-2005020910-A2 | CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND CORTICOTROPIN RELEASING FACTOR ANTAGONIST COMPOSITIONS FOR TREATING ISCHEMIC MEDIATED CNS DISORDERS OR INJURIES | PHARMACIA CORPORATION (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005018563-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A PHOSPHODIESTERASE INHIBITOR FOR THE TREATMENT OF ISCHEMIC MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005018563-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A PHOSPHODIESTERASE INHIBITOR FOR THE TREATMENT OF ISCHEMIC MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005018569-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005018569-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005018564-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A LOW-MOLECULAR-WEIGHT HEPARIN FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| EP-1509217-A1 | MONOTHERAPY FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS WITH CYCLOOXYGENASE-2 (COX 2) INHIBITOR(S) | Pharmacia Corporation (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2005016243-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN ANTIOXIDANT AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| EP-1505962-A2 | MONOTHERAPY FOR THE TREATMENT OF PARKINSON'S DISEASE WITH CYCLOOXYGENASE-2 (COX 2) INHIBITOR(S) | Pharmacia Corporation (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | disclosed |
| WO-2005009354-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN IKK INHIBITOR FOR THE TREATMENT OF ISCHEMIC-MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY | PHARMACIA CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050026919-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | disclosed |
| WO-2005007106-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A NON-NMDA GLUTAMATE MODULATOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| WO-2005007106-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A NON-NMDA GLUTAMATE MODULATOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-01-13 | — | — | US | disclosed |
| EP-1494664-A2 | COMBINATIONS OF COX-2 INHIBITORS AND OTHER AGENTS FOR THE TREATMENT OF PARKINSON'S DISEASE | Pharmacia Corporation (US) | 2005-01-12 | — | — | EP | disclosed |
| WO-2005000294-A1 | SELECTIVE INHIBITOR AND AN ANTICONVULSANT AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA CORPORATION (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2005000297-A1 | TREATMENT OF MIGRAINE ACCOMPANIED BY NAUSEA | PHARMACIA CORPORATION (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004110378-A2 | TREATMENT ALZHEIMER'S DISEASE WITH R(-) 2-ARYLPROPONIC ACID NSAID ALONE OR IN COMBINATION WITH SELECTIVE COX-2 INHIBITOR | PHARMACIA CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004103286-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CHOLIMERGIC AGENT | PHARMACIA CORPORATION (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004103283-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CENTRAL NERVOUS SYSTEM STIMULANT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004100895-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST FOR THE TREATMENT OF ISCHEMIC MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA CORPORATION (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040235925-A1 | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof | PHARMACIA CORPORATION | 2004-11-25 | — | — | US | disclosed |
| US-20040229803-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders | PHARMACIA CORPORATION | 2004-11-18 | — | — | US | disclosed |
| US-20040224940-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2004-11-11 | — | — | US | disclosed |
| WO-2004093896-A1 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A POTASSIUM ION CHANNEL MODULATOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004093826-A2 | COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND 5-HT1B/1D AGONISTS FOR THE TREATMENT AND PREVENTION OF MIGRAINE | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004093814-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SODIUM CHANNEL BLOCKER | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004093816-A2 | COMPOSITIONS COMPRISING A SELECTIVE COX-2 INHIBITOR AND A CALCIUM MODULATING AGENT | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040220187-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders | PHARMACIA CORPORATION | 2004-11-04 | — | — | US | disclosed |
| WO-2004093816-A2 | COMPOSITIONS COMPRISING A SELECTIVE COX-2 INHIBITOR AND A CALCIUM MODULATING AGENT | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004093813-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CALCIUM MODULATING AGENT FOR THE TREATMENT OF PAIN, INFLAMMATION OR INFLAMMATION MEDIATED DISORDERS | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004093811-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SODIUM ION CHANNEL BLOCKER FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004093895-A1 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A POTASSIUM ION CHANNEL MODULATOR FOR THE TREATMENT OF PAIN, INFLAMMATION OR INFLAMMATION MEDIATED DISORDERS | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040214861-A1 | Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine | PHARMACIA CORPORATION | 2004-10-28 | — | — | US | disclosed |
| US-20040204411-A1 | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof | PHARMACIA CORPORATION | 2004-10-14 | — | — | US | disclosed |
| US-20040186154-A1 | Therapeutic combinations for cardiovascular and inflammatory indications | SEIBERT KAREN (US) | 2004-09-23 | — | — | US | disclosed |
| US-20040176378-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an amphetamine for the treatment of reduced blood flow to the central nervous system | PHARMACIA CORPORATION | 2004-09-09 | — | — | US | disclosed |
| US-20040171664-A1 | Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event | PHARMACIA CORPORATION | 2004-09-02 | — | — | US | disclosed |
| US-20040157848-A1 | Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents | PHARMACIA CORPORATION | 2004-08-12 | — | — | US | disclosed |
| WO-2004060361-A2 | COMBINATION OF REBOXETINE AND A CYCLOOXYGENASE-2 INHIBITOR | PHARMACIA CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060366-A1 | A METHOD FOR THE TREATMENT, PREVENTION, OR INHIBITION OF A CNS DISORDER AND/OR PAIN AND INFLAMMATION USING A COMBINATION OF DULOXETINE, VENLAFAXINE OR ATOMOXETINE AND A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND COMPOSITIONS THEREOF | PHARMACIA CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060366-A1 | A METHOD FOR THE TREATMENT, PREVENTION, OR INHIBITION OF A CNS DISORDER AND/OR PAIN AND INFLAMMATION USING A COMBINATION OF DULOXETINE, VENLAFAXINE OR ATOMOXETINE AND A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND COMPOSITIONS THEREOF | PHARMACIA CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040138296-A1 | Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease | PHARMACIA CORPORATION | 2004-07-15 | — | — | US | disclosed |
| WO-2004058354-A1 | COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND SELECTIVE SEROTONIN REUPTAKE INHIBITORS FOR THE TREATMENT OR PREVENTION OF A VASO-OCCLUSIVE EVENT | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| EP-1435956-A2 | THERAPEUTIC COMBINATIONS FOR CARDIOVASCULAR AND INFLAMMATORY INDICATIONS | Pharmacia Corporation (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2004056349-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HERPES VIRUS INFECTIONS USING CYCLOOXYGENASE-2 SELECTIVE INHIBITORS OR CYCLOOXYGENASE-2 INHIBITORS IN COMBINATION WITH ANTIVIRAL AGENTS | PHARMACIA CORPORATION (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20040127539-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
| WO-2004054575-A1 | COMBINATIONS OF VALSARTAN WITH COX-2 INHIBITORS | NOVARTIS AG (CH) | 2004-07-01 | — | — | WO | disclosed |
| US-20040122011-A1 | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy | PHARMACIA CORPORATION | 2004-06-24 | — | — | US | disclosed |
| WO-2004039371-A2 | COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF NEUROPATHIC PAIN | PHARMACIA CORPORATION (US) | 2004-05-13 | — | — | WO | disclosed |
| EP-1414526-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Pharmacia Corporation (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040082557-A1 | Methods for treating estrogen-dependent disorders | PHARMACIA ITALIA S.P.A. (IT) | 2004-04-29 | — | — | US | disclosed |
| US-20040072889-A1 | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia | PHARMACIA CORPORATION | 2004-04-15 | — | — | US | disclosed |
| EP-1406696-A1 | USE OF COMPOSITIONS COMPRISING CYCLOOXYGENASE-2 SELECTIVE INHIBITORS IN COMBINATION WITH RADIATION FOR INHIBITION OR PREVENTION OF CARDIOVASCULAR DISEASE | Pharmacia Corporation (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20040067992-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia | PHARMACIA CORPORATION | 2004-04-08 | — | — | US | disclosed |
| US-20040063752-A1 | Such as N-(2-cyclohexyloxynitrophenyl)methane sulfonamide | PHARMACIA CORPORATION | 2004-04-01 | — | — | US | disclosed |
| US-20040063751-A1 | Combination therapy for the treatment of amyotrophic lateral sclerosis (ALS) with cyclooxygenase-2 (COX-2) inhibitor(s) and a second drug | PHARMACIA CORPORATION | 2004-04-01 | — | — | US | disclosed |
| US-20040063697-A1 | Compositions of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event | PHARMACIA CORPORATION | 2004-04-01 | — | — | US | disclosed |
| WO-2004014430-A1 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CARBONIC ANHYDRASE INHIBITOR FOR THE TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014367-A2 | USE OF AN AMYLOID BETA VACCINATION IN COMBINATION WITH A SELECTIVE COX-2 INHIBITOR FOR THE TREATMENT OF ALZHEIMER'S DISEASE | PHARMACIA CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20040034083-A1 | Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s) | PHARMACIA CORPORATION | 2004-02-19 | — | — | US | disclosed |
| WO-2004004833-A1 | USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THROMBOLYTIC AGENTS FOR THE TREATMENT OR PREVENTION OF A VASO-OCCLUSIVE EVENT | PHARMACIA CORPORATION (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20040006100-A1 | Monotherapy for the treatment of parkinson's disease with cyclooxygenase-2 (COX 2) inhibitor(S) | PHARMACIA CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-20030236293-A1 | Compositions of tricyclic cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain | PHARMACIA CORPORATION | 2003-12-25 | — | — | US | disclosed |
| US-20030236308-A1 | Compositions of cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain | PHARMACIA CORPORATION | 2003-12-25 | — | — | US | disclosed |
| WO-2003101441-A1 | MONOTHERAPY FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS WITH CYCLOOXYGENASE-2 (COX 2) INHIBITOR(S) | PHARMACIA CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003101380-A2 | AMYOTROPHIC LATERAL SCLEROSIS TREATMENT WITH CYCLOOXYGENASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| US-20030225150-A1 | Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia | PHARMACIA CORPORATION | 2003-12-04 | — | — | US | disclosed |
| US-20030225054-A1 | Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-04 | — | — | US | disclosed |
| US-20030216410-A1 | Combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2003-11-20 | — | — | US | disclosed |
| WO-2003088959-A2 | TREATMENT OF PARKINSON'S DISEASE WITH CYCLOOXYGENASE-2 (COX 2) INHIBITOR(S) | PHARMACIA CORPORATION (US) | 2003-10-30 | — | — | WO | disclosed |
| WO-2003088958-A2 | COMBINATIONS OF COX-2 INHIBITORS AND OTHER AGENTS FOR THE TREATMENT OF PARKINSON’S DISEASE | PHARMACIA CORPORATION (US) | 2003-10-30 | — | — | WO | disclosed |
| US-20030199482-A1 | Therapeutic combinations for cardiovascular and inflammatory indications | PHARMACIA CORPORATION | 2003-10-23 | — | — | US | disclosed |
| US-20030087942-A1 | Method for the treatment and prevention of cachexia | WASHINGTON UNIVERSITY | 2003-05-08 | — | — | US | disclosed |
| WO-2003020268-A1 | METHOD FOR THE TREATMENT AND PREVENTION OF CACHEXIA | WASHINGTON UNIVERSITY (US) | 2003-03-13 | — | — | WO | disclosed |
| US-20030035795-A1 | Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor | GARDELL STEPHEN J (US) | 2003-02-20 | — | — | US | disclosed |
| US-20030035795-A1 | Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor | GARDELL STEPHEN J (US) | 2003-02-20 | — | — | US | disclosed |
| US-20030013739-A1 | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia | PHARMACIA CORPORATION | 2003-01-16 | — | — | US | disclosed |
| WO-2002096516-A1 | USE OF COMPOSITIONS COMPRISING CYCLOOXYGENASE-2 SELECTIVE INHIBITORS IN COMBINATION WITH RADIATION FOR INHIBITION OR PREVENTION OF CARDIOVASCULAR DISEASE | PHARMACIA CORPORATION (US) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002078626-A2 | THERAPEUTIC COMBINATIONS FOR CARDIOVASCULAR AND INFLAMMATORY INDICATIONS | PHARMACIA CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020128267-A1 | Method of using COX-2 inhibitors in the treatment and prevention of ocular COX-2 mediated disorders | PHARMACIA CORPORATION | 2002-09-12 | — | — | US | disclosed |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2002-08-01 | — | — | US | disclosed |
| US-20020077328-A1 | Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain | PHARMACIA CORPORATION | 2002-06-20 | — | — | US | disclosed |
| CN-1066726-C | Pyrrole derivatives | HOFFMANN LA ROCHE (CH) | 2001-06-06 | — | — | CN | disclosed |
| US-5622948-A | ANALGESICS | SYNTEX (U.S.A.) INC. (US) | 1997-04-22 | — | — | US | disclosed |
| CN-1132206-A | Pyrrole derivatives | HOFFMANN LA ROCHE (CH) | 1996-10-02 | — | — | CN | disclosed |
| JP-H08208639-A | PYRROLE DERIVATIVE | F HOFFMANN LA ROCHE AG | 1996-08-13 | — | — | JP | disclosed |
| EP-0714895-A1 | Pyrrole derivatives | F. Hoffmann-La Roche AG (CH) | 1996-06-05 | — | — | EP | disclosed |
| EP-0714895-A1 | Pyrrole derivatives | F. Hoffmann-La Roche AG (CH) | 1996-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192588-A1 | CANNABIDIOLIC ACID (CBDA) DERIVATIVES AND USES THEREOF | CNR2, CNR1, GPR18 | ABCB11 931/4885PTGS2 1908/4885CYP1A2 301/4885 |
| US-20240277659-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | HPGDS, PTGIS, PTGDR2 | ABCB11 4411/4885PTGS2 19/4885CYP1A2 3825/4885 |
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | TPH2, TPH1, HTR2A | ABCB11 2587/4885PTGS2 15/4885CYP1A2 294/4885 |
| US-20100323014-A1 | NANOPARTICLES COMPRISING A NON-IONIZABLE CELLULOSIC POLYMER AND AN AMPHIPHILIC NON-IONIZABLE BLOCK COPOLYMER | LRBA, CEL, TNNC1 | ABCB11 269/4885PTGS2 3985/4885CYP1A2 1506/4885 |
| US-20240058333-A1 | TREATMENT AND PREVENTION OF SLEEP DISORDERS | HCRTR1, HCRTR2, MTNR1A | ABCB11 2201/4885PTGS2 2646/4885CYP1A2 380/4885 |
| US-20060105961-A1 | Method of using a cox-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia | TOP2A, TOP2B, TOP1 | ABCB11 1689/4885PTGS2 4/4885CYP1A2 191/4885 |
| US-20030216410-A1 | Combination therapy for the treatment of cancer | PTGS2, PTGES2, PTGFR | ABCB11 4073/4885PTGS2 1/4885CYP1A2 1647/4885 |
| US-20110130390-A1 | Use of COX-2 Inhibitors for the Treatment of Schizophrenia, Delusional Disorders, Affective Disorders, Autism or Tic Disorders | PTGES2, PTGER2, PTGDR2 | ABCB11 4601/4885PTGS2 4/4885CYP1A2 194/4885 |
| US-20040067992-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia | CA2, CA1, CA4 | ABCB11 2949/4885PTGS2 7/4885CYP1A2 263/4885 |
| US-12478609-B2 | Combination therapies using immuno-DASH inhibitors and PGE2 antagonists | HPGDS, PTGIS, PTGDR2 | ABCB11 4411/4885PTGS2 19/4885CYP1A2 3825/4885 |
| US-20210353652-A1 | TUMOR MICROENVIRONMENT-ACTIVATED DRUG-BINDER CONJUGATES, AND USES RELATED THERETO | CD47, VCAM1, CD44 | ABCB11 1347/4885PTGS2 582/4885CYP1A2 4074/4885 |
| US-20020077328-A1 | Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain | PTGIR, VASP, TRPV2 | ABCB11 3714/4885PTGS2 4/4885CYP1A2 283/4885 |
| US-20100266692-A1 | NANOPARTICLES COMPRISING A NON-IONIZABLE POLYMER AND AN ANIONIC CELLULOSIC POLYMER | CEL, TNNC1, MGAM | ABCB11 413/4885PTGS2 3620/4885CYP1A2 1159/4885 |
| US-20050054646-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders | TXNRD2, PRDX5, PTGS2 | ABCB11 3587/4885PTGS2 3/4885CYP1A2 627/4885 |
| US-20260007660-A1 | TREATMENT AND PREVENTION OF SLEEP DISORDERS | CRY1, PER2, SLC6A1 | ABCB11 262/4885PTGS2 3894/4885CYP1A2 317/4885 |
| US-20050107387-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders | PPARA, PPARG, PTGER2 | ABCB11 2850/4885PTGS2 10/4885CYP1A2 928/4885 |
| US-12370191-B2 | Treatment and prevention of sleep disorders | HCRTR1, HCRTR2, MTNR1A | ABCB11 2201/4885PTGS2 2646/4885CYP1A2 380/4885 |
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | KCNJ2, KCNN2, KCNK2 | ABCB11 1366/4885PTGS2 4/4885CYP1A2 1279/4885 |
| US-20050143360-A1 | Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea | PTGS2, PTGES2, PTGER2 | ABCB11 3881/4885PTGS2 1/4885CYP1A2 48/4885 |
| US-20040224940-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of central nervous system damage | PTGS2, TRPV1, SCN2A | ABCB11 1067/4885PTGS2 1/4885CYP1A2 1016/4885 |
| US-20230390241-A1 | DASH INHIBITORS, AND USES RELATED THERETO | CD2BP2, PCNA, CD2 | ABCB11 4316/4885PTGS2 2358/4885CYP1A2 4526/4885 |
| US-20030119895-A1 | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PTGS2, PTGES2, PTGS1 | ABCB11 2937/4885PTGS2 1/4885CYP1A2 58/4885 |
| US-20040220187-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders | TRPV1, TRPV2, TRPA1 | ABCB11 818/4885PTGS2 5/4885CYP1A2 453/4885 |
| US-20030225150-A1 | Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia | TOP2A, TOP2B, TOP1 | ABCB11 1689/4885PTGS2 4/4885CYP1A2 191/4885 |
| US-20220110951-A1 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL 2 FAMILY INHIBITOR | BCL2, BCL2L2, BCL2L1 | ABCB11 278/4885PTGS2 804/4885CYP1A2 1514/4885 |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | PCNA, CD2BP2, CCNO | ABCB11 4329/4885PTGS2 2466/4885CYP1A2 4597/4885 |
| US-20030114416-A1 | Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate | CSGALNACT1, PTGS2, PTGS1 | ABCB11 1534/4885PTGS2 2/4885CYP1A2 553/4885 |
| US-12384786-B2 | Cyclic molecules as Bruton's tyrosine kinase inhibitor | ABL1, BTK, LYN | ABCB11 3047/4885PTGS2 3974/4885CYP1A2 3089/4885 |
| US-20040063751-A1 | Combination therapy for the treatment of amyotrophic lateral sclerosis (ALS) with cyclooxygenase-2 (COX-2) inhibitor(s) and a second drug | SMN1; SMN2, PTGS2, PTGES2 | ABCB11 1152/4885PTGS2 2/4885CYP1A2 381/4885 |
| US-20040204411-A1 | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof | TPH2, MAOA, MAOB | ABCB11 2448/4885PTGS2 6/4885CYP1A2 4/4885 |
| US-20100215747-A1 | NANOPARTICLES COMPRISING IONIZABLE, POORLY WATER SOLUBLE CELLULOSIC POLYMERS | CEL, GYS1, TNNC1 | ABCB11 561/4885PTGS2 3826/4885CYP1A2 1946/4885 |
| US-20040122011-A1 | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy | PTGES2, PTGS2, PTGIS | ABCB11 2590/4885PTGS2 2/4885CYP1A2 505/4885 |
| US-20040044028-A1 | Combinations of omega-3 fatty acids and cyclooxygenase-2 inhibitors for treatment or prevention of cardiovascular disease and treatment or prevention of cancer | PTGES3, PTGER3, PTGES2 | ABCB11 4192/4885PTGS2 8/4885CYP1A2 173/4885 |
| US-11369599-B2 | Melt-extruded solid dispersions containing an apoptosis-inducing agent | BCL2, BAX, BCL2L1 | ABCB11 229/4885PTGS2 1930/4885CYP1A2 3584/4885 |
| US-20080293679-A1 | Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of COX inhibitors | LPL, ALOX12, LCLAT1 | ABCB11 2427/4885PTGS2 9/4885CYP1A2 473/4885 |
| US-20040157848-A1 | Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents | PTGS2, PTGES2, PTGS1 | ABCB11 4489/4885PTGS2 1/4885CYP1A2 578/4885 |
| US-20240197757-A1 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL 2 FAMILY INHIBITOR | BCL2, BCL2L2, BCL2L1 | ABCB11 284/4885PTGS2 821/4885CYP1A2 1288/4885 |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | CASP1, CASP2, APAF1 | ABCB11 2935/4885PTGS2 24/4885CYP1A2 2686/4885 |
| US-20040214861-A1 | Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine | HTR1B, HTR1D, HTR1A | ABCB11 2017/4885PTGS2 25/4885CYP1A2 255/4885 |
| US-20040063697-A1 | Compositions of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event | PTGIS, PTGIR, PTGS2 | ABCB11 2639/4885PTGS2 3/4885CYP1A2 657/4885 |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | TOP2A, TOP2B, TOP1 | ABCB11 2616/4885PTGS2 4/4885CYP1A2 854/4885 |
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | ABCB11 4405/4885PTGS2 171/4885CYP1A2 4466/4885 |
| US-20050187172-A1 | Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia | TOP2A, TOP2B, TOP1 | ABCB11 1261/4885PTGS2 4/4885CYP1A2 177/4885 |
| US-20030013739-A1 | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia | PTGS2, PTGES2, PTGS1 | ABCB11 4467/4885PTGS2 1/4885CYP1A2 382/4885 |
| US-20040006100-A1 | Monotherapy for the treatment of parkinson's disease with cyclooxygenase-2 (COX 2) inhibitor(S) | PTGS2, PTGES2, PTGS1 | ABCB11 1121/4885PTGS2 1/4885CYP1A2 240/4885 |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | ABCB11 2935/4885PTGS2 24/4885CYP1A2 2686/4885 |
| US-20220151972-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | CNR2, CNR1, FAAH | ABCB11 2096/4885PTGS2 2331/4885CYP1A2 1347/4885 |
| US-20040235925-A1 | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof | TPH2, BDNF, HTR2A | ABCB11 4603/4885PTGS2 86/4885CYP1A2 10/4885 |
| US-20040034083-A1 | Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s) | PTGES2, PTGS2, PTGER2 | ABCB11 980/4885PTGS2 2/4885CYP1A2 173/4885 |
| US-20250134886-A1 | SLEEP DISORDER TREATMENT AND PREVENTION | HCRTR2, HCRTR1, CRY1 | ABCB11 2169/4885PTGS2 3093/4885CYP1A2 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.